ArticleCancer cell2018
Molecular Signatures of Regression of the Canine Transmissible Venereal Tumor.
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 66 citations in OpenAlex.
- Article
- No Evidence for Distinct Transcriptomic Subgroups of Devil Facial Tumor Disease (DFTD).Evolutionary applications · 2025Article
- Gene expression in soft-shell clam (Mya arenaria) transmissible cancer reveals survival mechanisms during host infection and seawater transfer.PLoS genetics · 2025Article
- Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers.Annual review of biomedical data science · 2024Review
- Divergent DNA methylation patterns and gene expression in MYC andVeterinary world · 2024Article
- Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility.iScience · 2023Article
- Bridging clinic and wildlife care with AI-powered pan-species computational pathology.Nature communications · 2023Article
- Canine transmissible venereal tumour established in immunodeficient mice reprograms the gene expression profiles associated with a favourable tumour microenvironment to enable cancer malignancy.BMC veterinary research · 2022Article
- The differentiation state of the Schwann cell progenitor drives phenotypic variation between two contagious cancers.PLoS pathogens · 2021Article
- Article
- Transmissible Cancers in an Evolutionary Perspective.iScience · 2020Review
- Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii).Cellular and molecular life sciences : CMLS · 2020Review
- gga-microRNA-375 negatively regulates the cell cycle and proliferation by targeting Yes-associated protein 1 in DF-1 cells.Experimental and therapeutic medicine · 2020Article
- Disease swamps molecular signatures of genetic-environmental associations to abiotic factors in Tasmanian devil (Sarcophilus harrisii) populations.Evolution; international journal of organic evolution · 2020Article
- The evolution of resistance and tolerance as cancer defences.Parasitology · 2020Article
- Article
- Somatic evolution and global expansion of an ancient transmissible cancer lineage.Science (New York, N.Y.) · 2019Article
- Article
- The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease.Cancer cell · 2019Article
- Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
The canine transmissible venereal tumor (CTVT) is a clonally transmissible cancer that regresses spontaneously or after treatment with vincristine, but we know little about the regression mechanisms. We performed global transcriptional, methylation, and functional pathway analyses on serial biopsies of vincristine-treated CTVTs and found that regression occurs in sequential steps; activation of the innate immune system and host epithelial tissue remodeling followed by immune infiltration of the tumor, arrest in the cell cycle, and repair of tissue damage. We identified CCL5 as a possible driver of CTVT regression. Changes in gene expression are associated with methylation changes at specific intragenic sites. Our results underscore the critical role of host innate immunity in triggering cancer regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.